For a young, fit patient with newly diagnosed Stage IV high risk (IPI >2) DLBCL - germinal center subtype, what would be your preferred treatment approach in light of the FRONT-mind trial comparing Tafa-Len-RCHOP vs RCHOP?
With the recent publication of the FRONT-mind trial comparing Tafa+Len+RCHOP vs. RCHOP showing and 8% PFS benefit without an overall survival benefit, which patients are you using this new regimen in compared to Pola-RCHP or RCHOP alone?
Community PollStarted
For a young, fit patient with newly diagnosed Stage IV high risk (IPI >2) DLBCL - germinal center subtype, what would be your preferred treatment approach in light of the FRONT-mind trial comparing Tafa-Len-RCHOP vs RCHOP?
9 physicians have voted
Join Mednetto vote and see how they answered.